ID: ALA4456383

Max Phase: Preclinical

Molecular Formula: C25H25ClN2O3

Molecular Weight: 400.48

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1ccccc1N1CCN(Cc2cccc3c(=O)c4ccccc4oc23)CC1.Cl

Standard InChI:  InChI=1S/C25H24N2O3.ClH/c1-29-23-12-5-3-10-21(23)27-15-13-26(14-16-27)17-18-7-6-9-20-24(28)19-8-2-4-11-22(19)30-25(18)20;/h2-12H,13-17H2,1H3;1H

Standard InChI Key:  IQOFNIVTFWNCGN-UHFFFAOYSA-N

Associated Targets(non-human)

Htr2b Serotonin 2 (5-HT2) receptor (2078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 400.48Molecular Weight (Monoisotopic): 400.1787AlogP: 4.28#Rotatable Bonds: 4
Polar Surface Area: 45.92Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.61CX LogP: 4.48CX LogD: 4.42
Aromatic Rings: 4Heavy Atoms: 30QED Weighted: 0.48Np Likeness Score: -0.68

References

1. Żelaszczyk D, Jakubczyk M, Pytka K, Rapacz A, Walczak M, Janiszewska P, Pańczyk K, Żmudzki P, Słoczyńska K, Marona H, Waszkielewicz AM..  (2019)  Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.,  29  (21): [PMID:31537425] [10.1016/j.bmcl.2019.126679]

Source